Vanda Pharmaceuticals (VNDA) Gross Margin (2010 - 2026)

Vanda Pharmaceuticals has disclosed Gross Margin across 14 years of filings, most recently posting 93.89% for Q1 2026.

• Gross Margin for Q1 2026 came in at 93.89%, up 93.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 94.18% (down 16.0% YoY), and the FY2025 annual result was 93.96%, down 34.0% from the prior year.
• Gross Margin came in at 93.89% for Q1 2026 at Vanda Pharmaceuticals, up from 93.3% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 95.13% in Q4 2024 to a low of 90.32% in Q3 2022.
• The 5-year median for Gross Margin is 92.75% (2024), against an average of 92.82%.
• Across the five-year window, Gross Margin surged 277 bps in 2024 and plunged 183 bps in 2025, its largest moves.
• Vanda Pharmaceuticals' Gross Margin stood at 90.33% in 2022, then increased by 2 bps to 92.36% in 2023, then gained by 3 bps to 95.13% in 2024, then retreated by 2 bps to 93.3% in 2025, then climbed by 1 bps to 93.89% in 2026.
• The last three Gross Margin figures came in at 93.89% (Q1 2026), 93.3% (Q4 2025), and 94.75% (Q3 2025), per Business Quant data.